ArticleBrain and behavior2026
The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Effect of Ocrelizumab on Anti-JC Virus Antibody Index.Brain and behavior · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
PURPOSE/
introductionThe anti-JC virus (JCV) antibody index is used to stratify the risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS), particularly with natalizumab therapy. B-cell-depleting therapies may alter antibody levels and potentially confound the estimation of PML risk. This study evaluated the effect of ocrelizumab on anti-JCV antibody indices during the first 2 years of treatment.
methodsWe conducted a retrospective cohort study of 553 MS patients who initiated ocrelizumab between 2017 and 2019. Anti-JCV antibody indices were measured using the STRATIFY JCV assay at baseline and approximately every 6 months prior to subsequent infusions. Linear mixed-effects models were used to assess longitudinal changes in log-transformed JCV indices, adjusting for age, sex, and ethnicity. Secondary analyses evaluated serum B-cell counts and immunoglobulin levels. Sensitivity analyses addressed missing data. RESULTS/FINDING: There was no significant change in anti-JCV antibody index over time following ocrelizumab initiation (mean percent change per infusion cycle -0.049%, 95% CI: -0.449 to 0.351; p = 0.81). Results were consistent across sensitivity analyses and did not differ by age or sex. In contrast, peripheral B-cell counts declined significantly after treatment initiation and remained suppressed. Serum IgG, IgM, and IgA levels decreased modestly but significantly over time. JCV seroconversion occurred in 4.1% of initially seronegative patients, while seroreversion occurred in 6.6% of initially seropositive patients.
conclusionAnti-JCV antibody indices remain stable during the first 2 years of ocrelizumab treatment despite marked B-cell depletion and modest reductions in serum immunoglobulins. These findings suggest that existing PML risk stratification tools based on anti-JCV antibody indices remain applicable during early ocrelizumab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.